AGIO today
$32.82+$1.06 (+3.34%)close Nov 11, 2026Trend
DailyDowntrend (starting)
4 hourStrong Bullish
1 hourExpanding
15 minStrong Bullish
5 minStrong Bullish
Daily trend turns up above $46.00
Key levels
Resistance$40.50
Resistance$36.30
Support$32.31
Support$29.67
Latest news & SEC filings
AnalystBofA Securities trims its valuation view on Agios Pharmaceuticals
AnalystTruist keeps Buy rating on Agios Pharmaceuticals, cuts target to $35
AnalystTruist Securities keeps Buy rating on Agios Pharmaceuticals, cuts price target to $35
All AGIO news →About Agios Pharmaceuticals
Agios Pharmaceuticals develops and sells treatments for uncommon blood conditions. Its lead drug, mitapivat, is cleared for use in certain inherited red blood cell disorders, including pyruvate kinase deficiency and forms of thalassemia, across North America, Europe, the Middle East, and Great Britain. The company is also working on tebapivat for myelodysplastic syndromes and sickle cell disease, AG-181 for phenylketonuria, and AG-236 for polycythemia vera. It serves patients, doctors, and insurers.
Based on the company's 10-K filed Feb 12, 2026.
Nasdaq · Healthcare
AGIOS PHARMACEUTICALS, INC. (AGIO)
What Is the Price Target for AGIO?
SEPT Low Target
$32.00
SEPT Mid Target
$48.00
SEPT High Target
$62.00
Analyst Consensus
$48.00
Is AGIO a Buy or Sell Right Now?
Thesis
- •Revenue growing 48.0% YoY with STRONG trend — consistent growth.
- •SEC filings signal active product innovation — 1 new product/expansion keywords detected in 10-K. R&D investment rising.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for AGIO.
Start Free Trial →Is AGIO Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$46.59
25
Moat Score
NONE
2/9
Piotroski Score
9.6
Altman Z-Score
What Is Smart Money Doing with AGIO?
Insider Signal
SELLING
0 buys / 10 sells (90d)
Congress Signal
BUYING
5 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Gheuens Sarah | officer | Buy | 7,866 | $197K | Oct 26, 2026 |
| Gheuens Sarah | officer | Sale | 7,866 | $296K | Oct 26, 2026 |
| Gheuens Sarah | officer | Buy | 500 | $13K | Oct 22, 2026 |
| Gheuens Sarah | officer | Sale | 500 | $19K | Oct 22, 2026 |
| Gheuens Sarah | officer | Buy | 1,489 | $37K | Oct 21, 2026 |
| Gheuens Sarah | officer | Sale | 1,489 | $56K | Oct 21, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →AGIO Growth Story
Revenue YoY
48.0%
3yr Revenue CAGR
56.0%
EPS Growth YoY
-161.17%
FCF Growth YoY
3.6%
Revenue Trend
STRONG
Dark Pool Trades for AGIO
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for AGIO, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:00:08 | $32.82 | 29,900 | $$981K | SELL |
| 21:00:00 | $32.82 | 1,600 | $$53K | MIDPOINT |
| 20:55:36 | $32.80 | 2,837 | $$93K | MIDPOINT |
| 20:51:38 | $32.74 | 1,000 | $$33K | BUY |
| 20:45:36 | $32.73 | 1,000 | $$33K | SELL |
5 dark pool trades shown · $$1.2M preview volume
Real-time institutional flow, block trades, and net positioning
Options Flow for AGIO
PREVIEWSEPT Investing provides real-time options flow tracking for AGIO, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| CALL | $40 | Dec 18 | 37 | $$300 | 5 | SWEEP |
| PUT | $35 | Jan 21 | 436 | $$3800 | 4 | SWEEP |
| PUT | $35 | Jan 21 | 436 | $$3800 | 4 | SWEEP |
| PUT | $35 | Jan 21 | 436 | $$3800 | 4 | SWEEP |
| PUT | $35 | Jan 21 | 436 | $$1900 | 2 | SWEEP |
5 options trades shown · 20% calls
Unusual activity, GEX levels, max pain, and dealer positioning
What Traders Are Saying About AGIO
1 postsSEPT Investing hosts an active community of 3,500+ traders sharing real-time analysis, trade setups, and market discussion for AGIO. Join verified traders discussing price action, dark pool alerts, options flow, and AI-powered market intelligence.
Zone Setup -- $AGIO (AGIOS PHARMACEUTICALS, INC.) Price: $36.36 | Zone: $35.63 to $39.37 Conviction: HIGH | Analyst upside: +-3.6% Near support (20% of range) — reversal watch. Strong positive news ...
Join 3,500+ traders discussing AGIO in real-time
Trade ideas, setups, dark pool alerts, and AI-powered analysis
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for AGIOS PHARMACEUTICALS, INC. (AGIO) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →AGIO — frequently asked questions
What is AGIO stock price today?
AGIOS PHARMACEUTICALS, INC. (AGIO) is at $32.82, up 3.34% (+$1.06) at the Nov 11, 2026 close.
Why is AGIO stock moving today?
Latest AGIO news — Nov 7, 2026: BofA Securities trims its valuation view on Agios Pharmaceuticals · Nov 7, 2026: Truist keeps Buy rating on Agios Pharmaceuticals, cuts target to $35
Why did AGIO stock move on Oct 30, 2026?
Agios Pharmaceuticals shares fell 2.82% to close at $30.55 on Monday, trading between a high of $33.00 and a low of $29.80 on volume of about 2.74 million shares. The decline followed news that the FDA has pushed back its target decision date for the sickle cell disease drug mitapivat to February 1, 2027, giving the agency more time to complete its review.
What is the AGIO price target?
The average analyst price target for AGIO is $48.00, ranging from $32 to $62, based on 7 analysts.
What do analysts rate AGIO?
Analyst ratings for AGIO: 0 Buy, 19 Hold, 0 Sell — consensus Hold.
Did AGIO beat earnings?
AGIO last reported on Nov 5, 2026: EPS -$1.09 vs -$1.24 expected — a beat of 12.1%.
Does AGIO pay a dividend?
AGIO does not currently pay a dividend.
What are AGIO support and resistance levels?
Support: $32.31, $29.67, $26.89. Resistance: $36.30, $40.50, $44.09.
What are insiders doing with AGIO?
Insider activity: SELLING, 0 buys and 10 sells in the last 90 days.
What is the latest news on AGIO?
Nov 7, 2026: BofA Securities trims its valuation view on Agios Pharmaceuticals · Nov 7, 2026: Truist keeps Buy rating on Agios Pharmaceuticals, cuts target to $35 · Nov 6, 2026: Truist Securities keeps Buy rating on Agios Pharmaceuticals, cuts price target to $35